Galapagos creates Fidelta, a third Galapagos service division
(Thomson Reuters ONE) -
Mechelen, Belgium; 15 January 2013 - Galapagos NV (Euronext: GLPG) announced
today that the research site in Zagreb, Croatia, will form the basis of a newly
created service division, called Fidelta. Next to BioFocus and Argenta, this is
the third service division of Galapagos.
In September 2010 Galapagos acquired GlaxoSmithKline's state-of-the-art research
center in Zagreb, Croatia, accessing capabilities to resource research programs
from molecule through to the clinic for internal R&D programs. In order to
enhance efficient use of these facilities, Galapagos has re-focused the Zagreb
organization from internal to external outsourcing.
Fidelta is an exciting new drug discovery service company, being launched in the
year that Croatia joins the European Union. The 100-staff team at Fidelta have
a long history of successful drug discovery within Pliva, GlaxoSmithKline and
Galapagos. Fidelta has extensive chemistry, pharmacology (both in vitro and in
vivo), biomarker, toxicology and ADME/PK capabilities, with specific experience
in inflammation, infectious, metabolic, and oncology diseases. The company has
the know-how and resources to take projects from inception to the clinic and
will differentiate from Argenta and BioFocus through its expertise in in vivo
pharmacology, toxicology and inflammatory models in particular. Fidelta will be
led by Phil Dudfield, who has extensive experience in drug discovery within
large pharma and Galapagos and 5 years running fee-for-service groups at
BioFocus.
"With the creation of a third service division we can offer a broader range of
services to our customers," said Onno van de Stolpe, CEO of Galapagos. "With
this change we can further strengthen our worldwide leadership position in drug
discovery services, ranging from target discovery all the way through to the
delivery of preclinical candidates, in key disease areas for our clients."
About Fidelta
Fidelta makes the difference in efficacy and safety, combining expertise in the
areas of chemistry, pharmacology, ADME/PK and toxicology in its offering of
integrated discovery services. The company has a long history of fully
integrated drug discovery programs with primary expertise in the areas of
inflammation and anti-infective research, but has also been successful in the
areas of oncology, CNS, cardiovascular and metabolic diseases. Fidelta's
extensive AAALAC accredited in vivo capabilities afford the possibility to take
projects all the way to the clinic. Fidelta has more than 100 scientists
averaging over 11 years experience in the pharma industry, and more than 60%
with PhD and international experience gained at prestigious universities in
Europe and the US. More info at www.fidelta.eu
About Galapagos
Galapagos (Euronext: GLPG; OTC: GLPYY) is a mid-size clinical stage
biotechnology company specialized in the discovery and development of small
molecule and antibody therapies with a novel mode-of-action. The Company is
progressing four clinical, six pre-clinical, and 30 discovery programs in cystic
fibrosis, inflammation, antibiotics, metabolic disease, and other indications.
Its lead program is GLPG0634, an orally-available, selective inhibitor of JAK1,
for the treatment of rheumatoid arthritis and potentially other inflammatory
diseases. In two four-week Phase 2 studies, GLPG0634 showed improvement in the
signs and symptoms of rheumatoid arthritis and a unique safety profile. A 6
month Phase 2b study is expected to start Q2 2013 with top line data expected in
Q4 2014. AbbVie and Galapagos signed a worldwide license agreement whereby
AbbVie will be responsible for further development and commercialization after
Phase 2b. Galapagos is also progressing two other clinical development programs
with clinical readouts expected in 2013: GLPG0187, a novel integrin receptor
antagonist in development for metastasis, is in a Phase 1b patient study;
GLPG0974 is the first inhibitor of GPR43 to be evaluated clinically for the
treatment of IBD. This program is in a second Phase 1 study and will start a
Proof of Concept Phase 2 study in Q2 2013.
The Galapagos Group, including fee-for-service companies BioFocus, Argenta and
Fidelta, has over 800 employees and operates facilities in five countries, with
global headquarters in Mechelen, Belgium. Further information about the company
and its drug development programs can be found online at: www.glpg.com
Contact
Galapagos NV
Onno van de Stolpe, CEO
Tel: +31 6 2909 8028
ir(at)glpg.com
Fidelta
Phil Dudfield, Managing Director
Tel: +385 1 8886523
Galapagos forward-looking statements
This release may contain forward-looking statements, including, without
limitation, statements containing the words "believes," "anticipates,"
"expects," "intends," "plans," "seeks," "estimates," "may," "will," "could,"
"stands to," and "continues," as well as similar expressions. Such forward-
looking statements may involve known and unknown risks, uncertainties and other
factors which might cause the actual results, financial condition, performance
or achievements of Galapagos, or industry results, to be materially different
from any historic or future results, financial conditions, performance or
achievements expressed or implied by such forward-looking statements. Given
these uncertainties, the reader is advised not to place any undue reliance on
such forward-looking statements. These forward-looking statements speak only as
of the date of publication of this document. Galapagos expressly disclaims any
obligation to update any such forward-looking statements in this document to
reflect any change in its expectations with regard thereto or any change in
events, conditions or circumstances on which any such statement is based, unless
required by law or regulation.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Galapagos NV via Thomson Reuters ONE
[HUG#1670331]
Unternehmensinformation / Kurzprofil:
Datum: 15.01.2013 - 07:31 Uhr
Sprache: Deutsch
News-ID 219395
Anzahl Zeichen: 6987
contact information:
Town:
Mechelen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 221 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Galapagos creates Fidelta, a third Galapagos service division"
steht unter der journalistisch-redaktionellen Verantwortung von
Galapagos NV (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
